Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:28:06 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:ABBV - ABBVIE INC - https://www.abbvie.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABBV - Z5.0222.05·225.210.1223.43+4.392.06,067.11,349,89257,420218.75  225.82  218.5001244.81  164.3919:56:02Feb 0415 min RT 2¢

Recent Trades - Last 10 of 57420
Time ETExPriceChangeVolume
19:56:02Z224.004.981
19:48:54Z223.2454.2251
19:46:55Z224.9555.9351
19:20:16Z223.2454.2251
19:08:23Z223.2454.2251
19:07:56Z225.005.981
18:56:55Z224.105.0814
18:52:05Z224.105.081
18:40:49Z224.605.581
18:40:46Z224.004.981

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 07:48U:ABBVNews ReleaseAbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
2026-02-03 08:50U:ABBVNews ReleaseAllergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle(TM) Testimonial Program
2026-02-03 08:00U:ABBVNews ReleaseAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ(TM)) in Adults and Adolescents With Vitiligo
2026-01-29 08:00U:ABBVNews ReleaseAbbVie Launches Love in Mind(TM) to Spotlight the Emotional Impact of Migraine on Romantic Relationships
2026-01-28 08:00U:ABBVNews ReleaseAllergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
2026-01-16 13:43U:ABBVNews ReleaseAbbVie Announces Topline Results for Epcoritamab (DuoBody(TM) CD3xCD20) from Phase 3 EPCORE(TM) DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2026-01-12 18:30U:ABBVNews ReleaseAbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
2026-01-12 07:30U:ABBVNews ReleaseAbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
2026-01-12 06:00U:ABBVNews ReleaseAbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
2026-01-12 06:00U:ABBVNews ReleaseWest Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose(TM) 3.5mL On-Body Delivery System to AbbVie
2026-01-07 08:00U:ABBVNews ReleaseAbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
2026-01-05 08:00U:ABBVNews ReleaseAbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-02 08:15U:ABBVNews ReleaseAbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
2025-11-28 07:01U:ABBVNews ReleaseSKYRIZI(TM) (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
2025-11-25 09:30U:ABBVNews ReleaseAbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
2025-11-24 08:00U:ABBVNews ReleaseAbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
2025-11-18 12:47U:ABBVNews ReleaseAbbVie Announces U.S. FDA Approval of EPKINLY(TM) (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
2025-11-14 12:30U:ABBVNews ReleaseAbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
2025-11-13 08:30U:ABBVNews ReleaseAbbVie Announces 20 Recipients of Migraine Career Catalyst Award(TM)
2025-11-12 08:30U:ABBVNews ReleaseAllergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence